admin – Page 2421 – Get News Story

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Xuanzhu Biopharmaceutical, Fochon Pharmaceuticals

“Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline Insight”

DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ALK+ Advanced NSCLC Pipeline Landscape. It covers the ALK+ Advanced NSCLC Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the ALK+ Advanced NSCLC Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that over three key companies are actively engaged in developing more than three therapies for treating Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Overview:

Lung cancer continues to be the leading cause of cancer-related deaths globally. The development of tyrosine kinase inhibitors (TKIs) targeting specific mutations has greatly enhanced treatment outcomes for patients with advanced non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) gene rearrangements are found in about 3–7% of NSCLC cases, resulting in the persistent activation of signaling pathways that drive tumor growth and survival.

Improved diagnostic methods like reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) now enable more precise detection of ALK rearrangements compared to older techniques. These advancements also facilitate monitoring of tumor progression and assist in guiding treatment decisions involving ALK inhibitors.

Crizotinib was the first FDA-approved ALK inhibitor, achieving response rates ranging from 57% to 74%. Nonetheless, resistance typically develops within a year due to ALK-dependent mutations or ALK-independent mechanisms, including activation of alternative signaling pathways. To address this challenge, second- and third-generation ALK TKIs have been introduced, demonstrating encouraging effectiveness in both systemic disease and central nervous system (CNS) involvement. Although the best treatment sequence and timing remain to be established, the growing availability of ALK inhibitors provides renewed hope for improving progression-free and overall survival in patients with ALK-positive NSCLC.

Request for a detailed insights report on Anaplastic lymphoma kinase Non-Small Cell Lung Cancer pipeline insights

“Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Report

DelveInsight’s report on the Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer pipeline highlights a dynamic field with more than three active companies developing over three therapies for this condition. Leading companies such as Xuanzhu Biopharmaceutical, Fochon Pharmaceuticals Ltd., Shenzhen TargetRx, Inc., and others are actively researching new treatments to advance the management of ALK-positive NSCLC.
Notable pipeline candidates under development include XZP-3621, SAF-189, among others.
On December 18, 2025, the FDA approved ensartinib for adults with ALK-positive locally advanced or metastatic NSCLC who had not previously received an ALK inhibitor. This approval was supported by the eXALT3 clinical trial, which showed ensartinib achieving a median progression-free survival (PFS) of 25.8 months, significantly longer than crizotinib’s 12.7 months.
Additionally, on April 18, 2025, the FDA approved alectinib as an adjuvant therapy following tumor resection in patients with ALK-positive NSCLC, based on results from the ALINA trial demonstrating a significant improvement in disease-free survival.ntly improved disease-free survival compared to platinum-based chemotherapy in this setting.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.

Download our free sample page report on Anaplastic lymphoma kinase Non-Small Cell Lung Cancer pipeline insights

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Emerging Drugs

XZP-3621: Xuanzhu Biopharmaceutical
SAF-189: Reata Pharmaceuticals

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Companies

Around three or more leading companies are actively engaged in developing treatments for Anaplastic Lymphoma Kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Among these, Xuanzhu Biopharmaceutical has drug candidates currently in the most advanced Phase III stage of development.

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapies and Key Companies: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Clinical Trials and advancements

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment

• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Assessment by Product Type

• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer By Stage

• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Assessment by Route of Administration

• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Assessment by Molecule Type

Download Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Sample report to know in detail about the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer treatment market @ Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Current Treatment Patterns

4. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)

7. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Discontinued Products

13. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Product Profiles

14. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Key Companies

15. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Unmet Needs

18. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Future Perspectives

19. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Xuanzhu Biopharmaceutical, Fochon Pharmaceuticals

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GSK

“PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline”

DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that over 25 major companies are actively engaged in developing more than 30 treatment therapies for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC).

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Overview:

Lung cancer remains one of the top causes of cancer-related deaths globally and is often associated with a poor prognosis. However, the advent of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the treatment approach for patients with non-small cell lung cancer (NSCLC). Blocking the PD-1 receptor and its ligand PD-L1 has shown significant therapeutic benefits and improved survival outcomes in both preclinical and clinical settings for patients with locally advanced or metastatic NSCLC.

PD-1 is a Type I transmembrane protein found on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells (DCs). Its two ligands, PD-L1 and PD-L2, are also Type I transmembrane proteins but differ in their expression patterns. PD-L1 is present on T cells, B cells, DCs, macrophages, various non-hematopoietic cells, and tumor cells. Structurally, PD-1 and its ligands include a signal sequence, an immunoglobulin (Ig) domain, transmembrane domains, and a short cytoplasmic tail.

When PD-1 binds to PD-L1 or PD-L2, it becomes phosphorylated at two intracellular tyrosine residues. This triggers the recruitment of phosphatases SHP-1 and SHP-2, which bind to the ITIM and ITSM motifs on PD-1, leading to the suppression of antigen receptor signaling. The PD-1/ligand interaction inhibits effector T-cell activity, whereas the binding of B7-1/B7-2 with CD28 supports T-cell proliferation.

Request for a detailed insights report on PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline insights

“PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapeutics Market.

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Report

DelveInsight’s PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report highlights a dynamic field with over 25 companies actively developing more than 30 therapies for PD-1+ NSCLC treatment.
Leading companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others are investigating new drug candidates to enhance the treatment options for this disease.
Notable pipeline therapies in various stages of development include Zimberelimab, PM8002, RPH075, among others.
In August 2025, the FDA approved AstraZeneca’s durvalumab for treating adult NSCLC patients post-surgery, broadening its application beyond advanced cases where surgery is not feasible. Earlier, in January 2023, the FDA approved pembrolizumab as an adjuvant therapy after surgical resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) market.

Download our free sample page report on PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline insights

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Emerging Drugs

Zimberelimab: Arcus Biosciences
PM8002: Biotheus
RPH075: R-Pharm

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Companies

Over 25 leading companies are actively working on developing therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC). Notably, Arcus Biosciences is among those with drug candidates currently in the most advanced stage of development, specifically Phase III.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapies and Key Companies: PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials and advancements

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Therapeutic Assessment

• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Product Type

• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) By Stage

• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Route of Administration

• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Molecule Type

Download PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Sample report to know in detail about the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment market @ PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Current Treatment Patterns

4. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Late-Stage Products (Phase-III)

7. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Discontinued Products

13. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Product Profiles

14. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Key Companies

15. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Key Products

16. Dormant and Discontinued Products

17. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Unmet Needs

18. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Future Perspectives

19. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GSK

EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux

“EGFR Non-Small Cell Lung Cancer Pipeline Analysis”

DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

According to DelveInsight, the EGFR Non-Small Cell Lung Cancer pipeline involves over 25 key companies actively engaged in developing more than 30 treatment therapies for EGFR Non-Small Cell Lung Cancer.

EGFR Non-Small Cell Lung Cancer Overview:

EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) is a lung cancer subtype caused by mutations in the EGFR gene, which leads to uncontrolled cell proliferation. It represents about 10-15% of NSCLC cases in Western populations and 30-50% in Asian populations, primarily affecting non-smokers, women, and patients with adenocarcinoma.

Early symptoms tend to be mild and include cough, chest pain, shortness of breath, and weight loss, making early diagnosis challenging. As the disease progresses, metastasis can result in bone pain, headaches, or neurological symptoms.

While the exact causes are not fully understood, both genetic factors and environmental exposures—such as secondhand smoke, air pollution, and radon—may play a role. The fact that many patients are non-smokers suggests alternative pathways in cancer development.

Diagnosis typically involves imaging techniques like X-rays, CT scans, and PET scans, alongside biopsies for molecular analysis. Liquid biopsy, which detects circulating tumor DNA, is an emerging non-invasive diagnostic method.

Treatment mainly consists of EGFR tyrosine kinase inhibitors (TKIs) that target the mutated receptor. First- and second-generation TKIs such as erlotinib, gefitinib, and afatinib are commonly used, but osimertinib is preferred due to its effectiveness against resistance mutations and brain metastases. When TKIs are ineffective, chemotherapy, immunotherapy, or combination treatments may be considered. Ongoing research aims to develop improved therapies.

Request for a detailed insights report on EGFR Non-Small Cell Lung Cancer pipeline insights

“EGFR Non-Small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the EGFR Non-Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report

DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report highlights a vibrant field with over 25 active companies developing more than 30 therapies for EGFR Non-Small Cell Lung Cancer treatment.
Leading companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics, and others are exploring new drug candidates to enhance treatment options.
Noteworthy pipeline therapies in various development stages include CLN-081, BPI-361175, G1T38, JANX008, among others.
In October 2025, results from a global clinical trial showed that combining amivantamab with lazertinib significantly improved progression-free survival in patients with advanced NSCLC, outperforming the current standard, osimertinib. This combination extended the median progression-free survival to 23.7 months compared to 16.6 months with osimertinib alone.

EGFR Non-Small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the EGFR Non-Small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR Non-Small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the EGFR Non-Small Cell Lung Cancer market.

Download our free sample page report on EGFR Non-Small Cell Lung Cancer pipeline insights

EGFR Non-Small Cell Lung Cancer Emerging Drugs

CLN-081: Cullinan Oncology
BPI-361175: Betta Pharmaceuticals
G1T38: G1 Therapeutics
JANX008: Janux Therapeutics

EGFR Non-Small Cell Lung Cancer Companies

Around 25 or more leading companies are involved in developing therapies for EGFR-positive Non-Small Cell Lung Cancer (EGFR+ NSCLC), with Cullinan Oncology having a drug candidate currently in the most advanced stage of development, Phase III.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging EGFR Non-Small Cell Lung Cancer Therapies and Key Companies: EGFR Non-Small Cell Lung Cancer Clinical Trials and advancements

EGFR Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment

• EGFR Non-Small Cell Lung Cancer Assessment by Product Type

• EGFR Non-Small Cell Lung Cancer By Stage

• EGFR Non-Small Cell Lung Cancer Assessment by Route of Administration

• EGFR Non-Small Cell Lung Cancer Assessment by Molecule Type

Download EGFR Non-Small Cell Lung Cancer Sample report to know in detail about the EGFR Non-Small Cell Lung Cancer treatment market @ EGFR Non-Small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. EGFR Non-Small Cell Lung Cancer Current Treatment Patterns

4. EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. EGFR Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)

7. EGFR Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. EGFR Non-Small Cell Lung Cancer Discontinued Products

13. EGFR Non-Small Cell Lung Cancer Product Profiles

14. EGFR Non-Small Cell Lung Cancer Key Companies

15. EGFR Non-Small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. EGFR Non-Small Cell Lung Cancer Unmet Needs

18. EGFR Non-Small Cell Lung Cancer Future Perspectives

19. EGFR Non-Small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the EGFR Non-Small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux

C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Novartis, Apollomics Inc., Abbvie, Janssen Research and Developm

“C-Met Mutated Non-Small Cell Lung Cancer Pipeline”

DelveInsight’s, “C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that over five key companies are actively engaged in developing more than five treatment therapies for C-Met Mutated Non-Small Cell Lung Cancer.

C-Met Mutated Non-Small Cell Lung Cancer Overview:

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by an overexpression of the C-Met tyrosine kinase receptor, which is commonly present in epithelial cells. Activation of C-Met results in phosphorylation at specific tyrosine residues (Y1003, Y1313, Y1230/1234/1235, Y1349, and Y1365), which triggers several downstream signaling pathways including RAS/ERK, PI3K/AKT, and cSRC kinase pathways. Through SRC activation, C-Met plays a crucial role in driving epithelial-mesenchymal transition, leading to increased levels of hepatocyte growth factor (HGF) and intratumoral C-Met expression—both of which are strongly associated with NSCLC biology and patient prognosis. NSCLC is primarily classified into three subtypes based on cell morphology: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Key risk factors for developing NSCLC include smoking, exposure to radiation, and contact with harmful substances such as asbestos, arsenic, and chromium.

Request for a detailed insights report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights

“C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the C-Met Mutated Non-Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report

DelveInsight’s C-Met Mutated Non-Small Cell Lung Cancer pipeline report highlights an active landscape with over five companies developing more than five therapies for the treatment of C-Met Mutated NSCLC.
Leading companies such as Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others are exploring new drug candidates to advance treatment options.
Notable pipeline therapies under development include EGF-816 (Nazartinib), APL 101 (Bozitinib), among others.
In May 2020, Novartis secured FDA approval for Tabrecta, an oral MET inhibitor targeting metastatic NSCLC with MET exon 14 skipping mutations (METex14). This approval was the first of its kind for this specific genetic alteration, with clinical trials showing an overall response rate of 68% in treatment-naïve patients and 41% in those previously treated.

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the C-Met Mutated Non-Small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for C-Met Mutated Non-Small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the C-Met Mutated Non-Small Cell Lung Cancer market.

Download our free sample page report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights

C-Met Mutated Non-Small Cell Lung Cancer Emerging Drugs

EGF-816 (Nazartinib): Novartis Oncology
APL 101 (Bozitinib): Appolomics Inc.

C-Met Mutated Non-Small Cell Lung Cancer Companies

More than five leading companies are actively working on therapies for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC). Notably, firms like Novartis Oncology have drug candidates in mid-to-late stages of development, including Phase III clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

C-Met Mutated Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

C-Met Mutated Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging C-Met Mutated Non-Small Cell Lung Cancer Therapies and Key Companies: C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials and advancements

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment

• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Product Type

• C-Met Mutated Non-Small Cell Lung Cancer By Stage

• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Route of Administration

• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Molecule Type

Download C-Met Mutated Non-Small Cell Lung Cancer Sample report to know in detail about the C-Met Mutated Non-Small Cell Lung Cancer treatment market @ C-Met Mutated Non-Small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. C-Met Mutated Non-Small Cell Lung Cancer Current Treatment Patterns

4. C-Met Mutated Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. C-Met Mutated Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)

7. C-Met Mutated Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. C-Met Mutated Non-Small Cell Lung Cancer Discontinued Products

13. C-Met Mutated Non-Small Cell Lung Cancer Product Profiles

14. C-Met Mutated Non-Small Cell Lung Cancer Key Companies

15. C-Met Mutated Non-Small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. C-Met Mutated Non-Small Cell Lung Cancer Unmet Needs

18. C-Met Mutated Non-Small Cell Lung Cancer Future Perspectives

19. C-Met Mutated Non-Small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Novartis, Apollomics Inc., Abbvie, Janssen Research and Developm

Aqua Tower Review: The Life-Saving Solution for the Coming Water Crisis

Build Your Own Portable Water Generator – Cut Bills & Beat Drought

Water is the most essential part of one’s life. No one can live their life without it. There is also no alternative for water. It is highly important and the biggest blessing for us. For this very reason, we need to understand to keep it safe and make sure there’s plenty of it so that we never run out of it. Because honestly what would we do if one day we run out of water? That truth is hitting harder than ever as water shortage becomes one of the greatest threats of the 21st century. From California’s dried-up reservoirs to entire African villages forced to walk miles for a single bucket, the crisis is already here and it’s only spreading fast. Experts warn that by 2030, water supply will decrease by 40% due to high demand. When this happens, safe, drinkable water will be the new gold. But unlike gold, you can’t store your way out of thirst.

That’s why the recent discovery of the Aqua Tower has caught so much attention. This isn’t just another expensive water filter or a temporary fix. It’s a new, innovative, highly functional device that can pull clean, safe drinking water.

What Is the Aqua Tower?

The Aqua Tower is a self-contained water generation and purification system. The best part about the aqua tower is that it works in any weather. It is designed to help you store your own water and to stop relying on city water systems and overpriced bottled water.

Aqua Tower is different from the other water storing methods. It does not depend upon rainfall or rivers. The Aqua Tower pulls moisture directly from the air and then purifies it to meet and exceed World Health Organization (WHO) drinking standards and stores it for immediate use.

It works day and night, in desert heat, coastal humidity, or even cold mountain air, ensuring you and your family have a permanent water source of your own no matter what happens in the outside world.

How Was it Discovered?

Richard Wilson came up with the Aqua Tower. He is an engineer who spent two decades working in drought filled villages and regions hit with disaster. Richard Wilson had seen the desperation of people walking miles just to get a bucket of dirty water. He’d seen soldiers in remote areas forced to collect their last drops. And he knew that the usual solutions, saving up in bottles, drilling wells, or building pipelines were too slow and too expensive. They also required a lot of labor and equipment. He knew all of this was impossible in war zones or post-disaster environments.

As soon as he identified the problem, he worked together with a team of engineers who had experience in both humanitarian work and military logistics. Their mission was to create a device that could make clean, safe drinking water anywhere on Earth without depending on rivers, rain, or infrastructure.

After years of testing and refinement, they perfected a breakthrough in Atmospheric Water Generation (AWG). AWG is the science of pulling water vapor directly from the air. The result was a compact, durable machine capable of producing gallons of fresh water every single day, even in the driest climates.

How the Aqua Tower Works?

The Aqua Tower work in four stages to give you clean and clear water:

1. Air Intake:

A powerful fan draws in air from the surroundings. This fan is also energy efficient.

2. Condensation Process:

Cooling coils are fitted to the fan. This causes water vapor to condense into droplets.

3. Filtration and Purification:

Condensed water is treated with several filters. BIO UV sterilization and mineral balancing removes bacteria, heavy metals, microplastics, and other harmful chemicals, making the water safe.

4 Water Storage:

The water which is now clean is stored in a sealed, food-grade tank. From here it is ready for use.

The Aqua Tower’s water production depend on the model. It can be between 20- to 40 litres per day. This is enough to run a household of 6 people for drinking, cooking, and essential use. And unlike other water systems, it doesn’t need any groundwater, rainfall, or city pipes. This means any sort of droughts, pollution, or natural failures won’t make a difference in Aqua Tower’s performance.

Pricing:

AWG technology was extremely expensive with units costing $10,000–$20,000. These were used exclusively by governments, military, and high-end resorts. Today, the Aqua Tower team has made it affordable for the average household without compromising performance.

Aqua Tower costs only $36.69! This is extremely cheap as compared to other water storage methods and the best part is that this is a one-time payment only. In the whole package of the Aqua Tower System you will get:

The Aqua Tower System manual.
Detailed schematics and blueprints.
A complete parts and materials list.
Step-by-step full-color video tutorials.

The manual is super easy to understand and follow as it feels as though the creator is right there in the room, guiding you through each step. It provides clear instructions. In addition, every purchase comes with unlimited support and customers can email their questions at any time and receive quick personal response.

The shortage of water is no longer a minor concern. It is an increasingly serious reality. Purchasing an Aqua Tower now is a wise financial decision as well as a personal safety measure. These units’ rental and resale values will only increase with the growing demand for private water solutions worldwide.

For investors, Aqua Tower is more than simply a product. It is an opening to the water security sector, one of the fastest-growing businesses of the century.

It also brings peace of mind to families. You won’t have to wait in line when the next drought hits, or the supply of bottled water runs out. At home, you’ll be filling your glass with safe, cool water that was produced by your very own Aqua Tower.

Aqua Tower is a proven technology. Anyone who wants safety and control over their most important resource should consider it. There will be uncertainty in the upcoming years. With Aqua Tower you are securing peace of mind and protecting your family’s health.

Media Contact
Company Name: News Zone
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://rebrand.ly/theaquatower

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aqua Tower Review: The Life-Saving Solution for the Coming Water Crisis

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Clinical, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline | Autolus, PersonGen Biotherapeutics, Pepromene Bio

“CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline”

DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that over five key companies are actively engaged in developing more than five CAR T-Cell Therapy treatments for Acute Lymphoblastic Leukemia.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Overview:

Acute Lymphoblastic Leukemia (ALL), also called acute lymphocytic leukemia, is a blood cancer that begins in lymphocytes, a type of white blood cell, and develops in the bone marrow, the main site of blood cell production. ALL progresses rapidly, spreading through the bloodstream to other organs such as the liver, spleen, and lymph nodes. It affects both children and adults, with risk factors including exposure to radiation, harmful chemicals like benzene, and infections of T-lymphocytes.

Chimeric Antigen Receptor (CAR) T-cell therapy, which genetically modifies T cells to express receptors that specifically target antigens on cancer cells, has shown significant success in tumor immunotherapy, especially for treating B-cell malignancies.

Request for a detailed insights report on CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline insights

“CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Therapeutics Market.

Key Takeaways from the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Report

DelveInsight’s CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report highlights an active and growing field with more than five companies developing over five therapies for this treatment area.
Leading companies such as Autolus, PersonGen Biotherapeutics, Pepromene Bio, Inc., Actinium Pharmaceuticals, and others are exploring new drug candidates to enhance treatment options for Acute Lymphoblastic Leukemia.
Notable pipeline therapies in various stages of development include AUTO 3, PCAR019, and others. In November 2024, the U.S. Food and Drug Administration (FDA) approved Aucatzyl, developed by Autolus Inc., for adults with relapsed or refractory B-cell precursor ALL, showing a 42% complete remission rate within three months in clinical trials.
Previously, in October 2021, the FDA approved Tecartus, produced by Kite, a Gilead Company, as the first CAR T-cell therapy for adult patients with relapsed or refractory B-cell precursor ALL. Clinical trials reported a 65% complete remission rate among evaluable patients.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia market.

Download our free sample page report on CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline insights

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs

AUTO 3: Autolus
PCAR019: PersonGen Biotherapeutics

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Companies

Over five leading companies are actively working on developing CAR T-cell therapies for Acute Lymphoblastic Leukemia. Notably, firms like Autolus have drug candidates in mid-to-late stages of development, including Phase I/II trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Therapies and Key Companies: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Clinical Trials and advancements

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Therapeutic Assessment

• CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Assessment by Product Type

• CAR T-Cell Therapy for Acute Lymphoblastic Leukemia By Stage

• CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Assessment by Route of Administration

• CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Assessment by Molecule Type

Download CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Sample report to know in detail about the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia treatment market @ CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Current Treatment Patterns

4. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Late-Stage Products (Phase-III)

7. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Discontinued Products

13. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Product Profiles

14. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Companies

15. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Products

16. Dormant and Discontinued Products

17. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Unmet Needs

18. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Future Perspectives

19. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Clinical, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline | Autolus, PersonGen Biotherapeutics, Pepromene Bio

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Xuanzhu Biopharmaceutical,

“Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline”

DelveInsight reports that over three key companies are actively working on developing more than three therapies for the treatment of Anaplastic Lymphoma Kinase (ALK) positive, advanced non–small cell lung cancer.

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Overview:

Lung cancer continues to be the leading cause of cancer-related deaths worldwide. The introduction of tyrosine kinase inhibitors (TKIs) has markedly improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) harboring targetable mutations. In 3–7% of NSCLC cases, rearrangements in the anaplastic lymphoma kinase (ALK) gene result in persistent activation of pathways that drive tumor growth and survival.

Advancements in diagnostic tools, such as reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS), have enhanced the accuracy of detecting ALK rearrangements, enabling more tailored treatment strategies. Crizotinib, the first FDA-approved ALK TKI, achieved response rates of 57–74%, but most patients develop resistance within about a year. Resistance arises from both ALK-dependent mutations and ALK-independent mechanisms, including activation of alternative signaling pathways.

Second- and third-generation ALK TKIs have shown high efficacy in both systemic disease and central nervous system (CNS) metastases, though the optimal treatment sequence is still under investigation. The expanding range of available ALK inhibitors offers new hope for prolonging progression-free and overall survival in ALK-positive NSCLC patients.

Request for a detailed insights report on Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer pipeline insights

“Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline Report

DelveInsight’s report on the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer pipeline highlights a strong development landscape, with over three active companies working on more than three therapies for this indication.
Key players include Xuanzhu Biopharmaceutical, Fochon Pharmaceuticals Ltd, Shenzhen TargetRx, Inc., and others, all focused on advancing novel treatments to enhance the therapeutic landscape.
Notable candidates in development include XZP-3621, SAF-189, and additional promising therapies at various stages of the pipeline.
On December 18, 2024, the FDA approved ensartinib for adult patients with ALK-positive locally advanced or metastatic NSCLC who had not previously been treated with an ALK inhibitor. Approval was supported by results from the eXALT3 trial, which reported a median progression-free survival (PFS) of 25.8 months with ensartinib versus 12.7 months with crizotinib.
Earlier, on April 18, 2024, the FDA approved alectinib as an adjuvant therapy for patients with ALK-positive NSCLC following tumor resection. Findings from the ALINA trial demonstrated that alectinib provided a significant improvement in disease-free survival compared to platinum-based chemotherapy.

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer market.

Download our free sample page report on Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer pipeline insights

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Emerging Drugs

XZP-3621: Xuanzhu Biopharmaceutical
SAF-189: Reata Pharmaceuticals

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Companies

Multiple leading companies are actively working on therapies for Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer, with Xuanzhu Biopharmaceutical having a drug candidate currently in the advanced Phase III clinical trial stage.

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Therapies and Key Companies: Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Clinical Trials and advancements

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline Therapeutic Assessment

• Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Assessment by Product Type

• Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer By Stage

• Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Assessment by Route of Administration

• Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Assessment by Molecule Type

Download Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Sample report to know in detail about the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer treatment market @ Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Current Treatment Patterns

4. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Late-Stage Products (Phase-III)

7. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Discontinued Products

13. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Product Profiles

14. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Key Companies

15. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Unmet Needs

18. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Future Perspectives

19. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Xuanzhu Biopharmaceutical,

Complicated Urinary Tract Infections Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Complicated Urinary Tract Infections Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Complicated Urinary Tract Infections pipeline landscape. It covers the Complicated Urinary Tract Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Complicated Urinary Tract Infections pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Complicated Urinary Tract Infections Pipeline Outlook Report

Key Takeaways from the Complicated Urinary Tract Infections Pipeline Report

In August 2025, Menarini Group announced a clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration.
DelveInsight’s Complicated Urinary Tract Infections pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Complicated Urinary Tract Infections treatment.
The leading Complicated Urinary Tract Infections Companies such as Spero Therapeutics, Jiangsu Hengrui Medicine Co., Everest Medicines, NeuroRx Inc., Pfizer and others.
Promising Complicated Urinary Tract Infections Pipeline Therapies such as Ceftazidime -avibactam, Cefepime, Eravacycline, Ertapenem, CXA-101, Sulopenem, NXL104/ceftazidime, Imipenem/Cilastatin and others.

Learn how leading Complicated Urinary Tract Infections Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Complicated Urinary Tract Infections Clinical Trials Assessment

Complicated Urinary Tract Infections Emerging Drugs Profile

TBP-PI-HBr: GSK/ Spero Therapeutics

Tebipenem pivoxil hydrobromide (HBr) is an orally administered carbapenem antibiotic developed by Spero Therapeutics, designed to address serious bacterial infections such as complicated urinary tract infections (cUTIs), including pyelonephritis. As the first oral carbapenem in development, tebipenem HBr offers a potential alternative to intravenous therapy, providing broad-spectrum antibacterial activity against multidrug-resistant Gram-negative pathogens. Its oral formulation supports earlier hospital discharge and improved outpatient management, making it a promising option in the evolving landscape of antimicrobial resistance and infection control. Currently, the drug is in the Phase III stage of its development for the treatment of Complicated Urinary Tract Infections.

NRX-101: NeuroRx, Inc.

NRX-101 is an investigational oral medication that combines D-cycloserine, an NMDA receptor antagonist, with lurasidone, an atypical antipsychotic, and is being explored for use in treating complicated urinary tract infections (cUTIs). The formulation leverages the antimicrobial properties of D-cycloserine, which has shown activity against resistant bacterial strains, and the neuroprotective and mood-stabilizing effects of lurasidone to potentially address both infection and associated symptoms such as delirium or behavioral disturbances in vulnerable populations. Its oral route of administration offers the advantage of outpatient treatment potential, especially in patients requiring step-down therapy after initial intravenous antibiotics. Currently, the drug is in Phase II stage of its development for the treatment of Complicated Urinary Tract Infections.

PF-07612577: Pfizer

PF-07612577 is an investigational antibiotic combination developed for the treatment of complicated urinary tract infections (cUTIs). It includes an intravenous β-lactamase inhibitor paired with a cephalosporin antibiotic, designed to combat multidrug-resistant gram-negative bacteria, including extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacterales. This combination works by inhibiting bacterial enzymes that degrade β-lactam antibiotics, thereby restoring the efficacy of the cephalosporin component. PF-07612577 aims to provide a potent treatment option for patients with limited alternatives due to antimicrobial resistance, making it especially valuable in hospital settings where resistant pathogens are a growing concern. Currently, the drug is in Phase I stage of its development for the treatment of Complicated Urinary Tract Infections.

The Complicated Urinary Tract Infections Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Complicated Urinary Tract Infections with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complicated Urinary Tract Infections Treatment.
Complicated Urinary Tract Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Complicated Urinary Tract Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Complicated Urinary Tract Infections market.

From early-stage research to late-phase Complicated Urinary Tract Infections Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Complicated Urinary Tract Infections Treatment Drugs

Complicated Urinary Tract Infections Companies

Spero Therapeutics, Jiangsu Hengrui Medicine Co., Everest Medicines, NeuroRx Inc., Pfizer and others.

Complicated Urinary Tract Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Complicated Urinary Tract Infections Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Stay updated with the latest Complicated Urinary Tract Infections Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Complicated Urinary Tract Infections Market Drivers and Barriers, and Future Perspectives

Scope of the Complicated Urinary Tract Infections Pipeline Report

Coverage- Global
Complicated Urinary Tract Infections Companies- Spero Therapeutics, Jiangsu Hengrui Medicine Co., Everest Medicines, NeuroRx Inc., Pfizer and others.
Complicated Urinary Tract Infections Pipeline Therapies- Ceftazidime -avibactam, Cefepime, Eravacycline, Ertapenem, CXA-101, Sulopenem, NXL104/ceftazidime, Imipenem/Cilastatin and others.
Complicated Urinary Tract Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Complicated Urinary Tract Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Complicated Urinary Tract Infections Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Complicated Urinary Tract Infections Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Complicated Urinary Tract Infections: Overview
Pipeline Therapeutics
Therapeutic Assessment
Complicated Urinary Tract Infections– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
TBP-PI-HBr: GSK/ Spero Therapeutics
Mid Stage Products (Phase II)
NRX-101: NeuroRx, Inc.
Early Stage Products (Phase I)
PF-07612577: Pfizer
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Complicated Urinary Tract Infections Key Companies
Complicated Urinary Tract Infections Key Products
Complicated Urinary Tract Infections- Unmet Needs
Complicated Urinary Tract Infections- Market Drivers and Barriers
Complicated Urinary Tract Infections- Future Perspectives and Conclusion
Complicated Urinary Tract Infections Analyst Views
Complicated Urinary Tract Infections Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complicated Urinary Tract Infections Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape

Fallopian Tube Cancer Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Fallopian Tube Cancer Pipeline Insight 2025” report provides comprehensive insights about 70+ Fallopian tube cancer companies and 70+ pipeline drugs in Fallopian Tube Cancer pipeline landscape. It covers the Fallopian Tube Cancer pipeline drug profiles, including clinical and nonclinical stage products. Fallopian tube cancer pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Fallopian Tube Cancer Pipeline Outlook Report

Key Takeaways from the Fallopian Tube Cancer Pipeline Report

In August 2025, Corcept Therapeutics announced a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
In August 2025, AbbVie conducted a study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα).
In August 2025, Imunon conducted a phase 3 study evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer.
In August 2025, Daiichi Sankyo conducted a study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The Phase 2 dose-optimization part of the study (Part A) intends to define the recommended dose based on safety and efficacy, while the Phase 3 (Part B) part of the study will compare R-DXd with Investigator’s choice of chemotherapy and further evaluate efficacy.
DelveInsight’s Fallopian Tube Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Fallopian Tube Cancer treatment.
The leading Fallopian Tube Cancer Companies such as ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics and others.
Promising Fallopian Tube Cancer Pipeline Therapies such as Bevacizumab, Trabectedin, Dexamethasone, epothilone b, Avastin, Docetaxel, Paclitaxel, BIBF 1120, Mirvetuximab soravtansine, Carboplatin, Sargramostim and others.

Learn how leading Fallopian Tube Cancer Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Fallopian Tube Cancer Clinical Trials Assessment

Fallopian Tube Cancer Emerging Drugs Profile

Mirvetuximab Soravtansine: ImmunoGen

Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4. It is currently in phase III stage of development and is being developed by Immunogen.

Tisotumab vedotin: Genmab/Seagen

Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody–drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.

Pembrolizumab: Merck & Co.

Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.

The Fallopian Tube Cancer Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Fallopian Tube Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fallopian Tube Cancer Treatment.
Fallopian Tube Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Fallopian Tube Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fallopian Tube Cancer market.

From early-stage research to late-phase Fallopian Tube Cancer Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Fallopian Tube Cancer Treatment Drugs

Fallopian Tube Cancer Companies

ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics and others.

Fallopian Tube Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Fallopian Tube Cancer Products have been categorized under various ROAs such as

Infusion
Intradermal
Intramuscular
Intranasal
Oral
Parenteral
Subcutaneous
Topical
Molecule Type

Fallopian Tube Cancer Products have been categorized under various Molecule types such as

Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type

Stay updated with the latest Fallopian Tube Cancer Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Fallopian Tube Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Fallopian Tube Cancer Pipeline Report

Coverage- Global
Fallopian Tube Cancer Companies- ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics and others.
Fallopian Tube Cancer Pipeline Therapies- Bevacizumab, Trabectedin, Dexamethasone, epothilone b, Avastin, Docetaxel, Paclitaxel, BIBF 1120, Mirvetuximab soravtansine, Carboplatin, Sargramostim and others.
Fallopian Tube Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Fallopian Tube Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Fallopian Tube Cancer Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Fallopian Tube Cancer Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Fallopian Tube Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Fallopian Tube Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Fallopian Tube Cancer Collaboration Deals
Late Stage Products (Phase III)
Mirvetuximab Soravtansine: ImmunoGen
Mid Stage Products (Phase II)
Gimatecan: Lee’s Pharmaceuticals
Early stage products (Phase I)
TG4050: Transgene
Inactive Products
Fallopian Tube Cancer Key Companies
Fallopian Tube Cancer Key Products
Fallopian Tube Cancer- Unmet Needs
Fallopian Tube Cancer- Market Drivers and Barriers
Fallopian Tube Cancer- Future Perspectives and Conclusion
Fallopian Tube Cancer Analyst Views
Fallopian Tube Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fallopian Tube Cancer Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape

Hidradenitis Suppurativa Pipeline Outlook Report 2025: Key 24+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Hidradenitis Suppurativa Pipeline Insight 2025” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the Hidradenitis Suppurativa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hidradenitis Suppurativa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hidradenitis Suppurativa Treatment Landscape. Click here to read more @ Hidradenitis Suppurativa Pipeline Outlook

Key Takeaways from the Hidradenitis Suppurativa Pipeline Report

In August 2025, Novartis Pharmaceuticals announced a study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
In August 2025, Incyte Corporation announced a study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
In August 2025, AbbVie conducted a study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed.
In August 2025, Sanofi organized a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study is to evaluate the efficacy and safety of SAR442970 compared to placebo.
DelveInsight’s Hidradenitis Suppurativa pipeline report depicts a robust space with 24+ active players working to develop 24+ pipeline therapies for Hidradenitis Suppurativa treatment.
The leading Hidradenitis Suppurativa Companies such as InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.
Promising Hidradenitis Suppurativa Pipeline Therapies such as Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.

Discover groundbreaking developments in Hidradenitis Suppurativa therapies! Gain in-depth knowledge of key Hidradenitis Suppurativa Clinical trials, emerging drugs, and market opportunities @ Hidradenitis Suppurativa Clinical Trials Assessment

Hidradenitis Suppurativa Emerging Drugs Profile

Vilobelimab: InflaRx

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated. Vilobelimab is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum, cancer and severe COVID‑19.

Secukinumab: Novartis

Secukinumab is the first and only fully human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)12,13. Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis, PsA and AS14-20. These data strengthen the position of Cosentyx as a treatment across AS, nr-axSpA, PsA and moderate to severe plaque psoriasis, supported by more than 500,000 patients treated worldwide since launch in 2015.

Avacopan: ChemoCentryx

Avacopan, approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory diseases. While the precise mechanism in ANCA vasculitis has not been definitively established, Avacopan, by blocking the complement 5a receptor (C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, is presumed to arrest the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA vasculitis. Avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).

Imsidolimab: AnaptysBio

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

Spesolimab: Boehringer Ingelheim

Spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogeneses of several autoimmune diseases, including GPP. Spesolimab is also under investigation for the prevention of GPP flares and for the treatment of other neutrophilic skin diseases, such as palmoplantar pustulosis (PPP) and hidradenitis suppurativa (HS).

Hidradenitis Suppurativa Market Drivers

Advancements in Research and Development
Rise in awareness about the disease

Hidradenitis Suppurativa Market Barriers

Stigma and Patient Reluctance
Complexity of the disease

The Hidradenitis Suppurativa Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.
Hidradenitis Suppurativa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market

Stay informed about the Hidradenitis Suppurativa pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hidradenitis Suppurativa Unmet Needs

Hidradenitis Suppurativa Companies

InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Hidradenitis Suppurativa Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Transform your understanding of the Hidradenitis Suppurativa Pipeline! See the latest progress in drug development and clinical research @ Hidradenitis Suppurativa Market Drivers and Barriers, and Future Perspectives

Scope of the Hidradenitis Suppurativa Pipeline Report

Coverage- Global
Hidradenitis Suppurativa Companies- InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics and others.
Hidradenitis Suppurativa Pipeline Therapies- Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.
Hidradenitis Suppurativa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hidradenitis Suppurativa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Gastroenterology Research–Access the Full Hidradenitis Suppurativa Pipeline Analysis Today! @ Hidradenitis Suppurativa Drugs and Companies

Table of Content

Introduction
Executive Summary
Hidradenitis Suppurativa: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hidradenitis Suppurativa – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Vilobelimab: InflaRx
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Spesolimab: Boehringer Ingelheim
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AT193: Azora Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hidradenitis Suppurativa Key Companies
Hidradenitis Suppurativa Key Products
Hidradenitis Suppurativa – Unmet Needs
Hidradenitis Suppurativa – Market Drivers and Barriers
Hidradenitis Suppurativa – Future Perspectives and Conclusion
Hidradenitis Suppurativa Analyst Views
Hidradenitis Suppurativa Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Pipeline Outlook Report 2025: Key 24+ Companies and Breakthrough Therapies Shaping the Future Landscape